Ivosidenib for advanced IDH1-mutant cholangiocarcinoma

被引：0
|
作者：
Gervaso, Lorenzo [1 ]
Pellicori, Stefania [1 ]
Fazio, Nicola [1 ]
机构：
[1] European Inst Oncol, Div Gastrointestinal Med Oncol & Neuroendocrine T, I-20141 Milan, Italy
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E370 / E370
页数：1
相关论文
共 50 条
  • [21] A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN IDH1-MUTANT DIFFUSE GLIOMA: UPDATED RESULTS
    Mellinghoff, Ingo
    Wen, Patrick
    Taylor, Jennie
    Taylor, Elizabeth
    Arrillaga-Romany, Isabel
    Ellingson, Benjamin
    Mahboub-Johnson, Paria
    Baron, Eric
    Hassan, Islam
    Steelman, Lori
    Clarke, Jennifer
    Cloughesy, Timothy
    NEURO-ONCOLOGY, 2024, 26
  • [22] Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    Mellinghoff, Ingo K.
    Lu, Min
    Wen, Patrick Y.
    Taylor, Jennie W.
    Maher, Elizabeth A.
    Arrillaga-Romany, Isabel
    Peters, Katherine B.
    Ellingson, Benjamin M.
    Rosenblum, Marc K.
    Chun, Saewon
    Le, Kha
    Tassinari, Ania
    Choe, Sung
    Toubouti, Youssef
    Schoenfeld, Steven
    Pandya, Shuchi S.
    Hassan, Islam
    Steelman, Lori
    Clarke, Jennifer L.
    Cloughesy, Timothy F.
    NATURE MEDICINE, 2023, 29 (03) : 615 - +
  • [23] Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.
    Dai, David
    Dinardo, Courtney Denton
    Stein, Eytan
    de Botton, Stephane
    Attar, Eyal C.
    Liu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 217 - 224
  • [25] Targeting mutant IDH1 in advanced cholangiocarcinoma
    Lai, Cheryl
    LANCET ONCOLOGY, 2019, 20 (11): : 1488 - 1488
  • [26] RELATIONSHIP OF IVOSIDENIB PLASMA CONCENTRATION TO HEART RATE-CORRECTED QT INTERVAL IN PATIENTS WITH IDH1-MUTANT ADVANCED HEMATOLOGIC MALIGNANCIES.
    Le, K.
    Poland, B.
    Dai, D.
    Fan, B.
    Liu, H.
    Attar, E. C.
    Hickman, D.
    Agresta, S. V.
    Yang, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S85 - S85
  • [27] Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
    Roboz, Gail J.
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Mims, Alice S.
    Prince, Gabrielle T.
    Altman, Jessica K.
    Arellano, Martha L.
    Donnellan, Will
    Erba, Harry P.
    Mannis, Gabriel N.
    Pollyea, Daniel A.
    Stein, Anthony S.
    Uy, Geoffrey L.
    Watts, Justin M.
    Fathi, Amir T.
    Kantarjian, Hagop M.
    Tallman, Martin S.
    Choe, Sung
    Dai, David
    Fan, Bin
    Wang, Hongfang
    Zhang, Vickie
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Hickman, Denice
    Liu, Hua
    Agresta, Samuel, V
    Wu, Bin
    Attar, Eyal C.
    Stone, Richard M.
    BLOOD, 2020, 135 (07) : 463 - 471
  • [28] Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma
    Aguado-Fraile, Elia
    Tassinari, Ania
    Ishii, Yuko
    Sigel, Carlie
    Lowery, Maeve A.
    Goyal, Lipika
    Gliser, Camelia
    Jiang, Liewen
    Pandya, Shuchi S.
    Wu, Bin
    Bardeesy, Nabeel
    Choe, Sung
    Deshpande, Vikram
    FUTURE ONCOLOGY, 2021, 17 (16) : 2057 - 2074
  • [29] Longitudinal Molecular Profiling in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib
    Choe, Sung
    Wang, Hongfang
    Roboz, Gail J.
    DiNardo, Courtney D.
    Stein, Eytan M.
    Mims, Alice S.
    Prince, Gabrielle T.
    Watts, Justin M.
    Fan, Bin
    Nejad, Parham
    Zhang, Vickie
    Liu, Hua
    Attar, Eyal C.
    Wu, Bin
    Stone, Richard M.
    BLOOD, 2020, 136
  • [30] Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes
    Lanman, Tyler A.
    Youssef, Gilbert
    Huang, Raymond
    Rahman, Rifaquat
    Desalvo, Matthew
    Flood, Thomas
    Hassanzadeh, Elmira
    Lang, Min
    Lauer, Jason
    Potter, Christopher
    Jiao, Albert
    Pan, Ian
    Cahill, Daniel P.
    Lan, Zhou
    Ospina, Juan Pablo
    Nakhate, Vihang
    Stec, Natalie E.
    Shi, Diana
    Bi, Wenya Linda
    Mcbrayer, Samuel K.
    Arrillaga-Romany, Isabel
    Lee, Eudocia Q.
    Chukwueke, Ugonma N.
    Nayak, Lakshmi
    Forst, Deborah A.
    Gerstner, Elizabeth R.
    Jordan, Justin T.
    Dietrich, Jorg
    Miller, Julie
    Batchelor, Tracy T.
    Reardon, David A.
    Wen, Patrick Y.
    Castro, L. Nicolas Gonzalez
    NEURO-ONCOLOGY ADVANCES, 2025, 7 (01)
12345